Healthcare, Pharma & Life Sciences

Hengrui Licenses Oral GLP-1/GIP Drug to Novo in $2.6B Deal

Image
Hengrui Licenses Oral GLP-1/GIP Drug to Novo in $2.6B Deal

Shanghai – – September 29, 2026 -- Hengrui Pharma has licensed its investigational obesity and diabetes drug HRS-1596 to Novo Nordisk in a deal worth up to 2.6 billion US dollars, including a 300 million dollar upfront payment.

Novo secures global rights excluding Greater China

Under the agreement, Novo obtains exclusive rights to develop, manufacture and commercialise HRS-1596 worldwide, excluding the Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan Region. Hengrui Pharma retains eligibility for royalties on net sales of the drug within Novo's licensed territory, on top of the milestone-based payments tied to development, regulatory and commercial targets.

iRegene's NouvSight001 Cleared for RP Trials in US and China

Chengdu, China – September 29, 2026 -- iRegene Therapeutics has secured clinical trial clearances in both China and the United States for NouvSight001, an off-the-shelf cell therapy targeting retinitis pigmentosa (RP), a retinal disease affecting roughly 1.5 million people worldwide.

China's NMPA clears Phase I/III trial while FDA grants Phase I/II clearance with special exemption

China's National Medical Products Administration authorized a Phase I/III trial to assess safety, tolerability and preliminary efficacy of NouvSight001 in RP patients. The U.S. FDA separately cleared a Phase I/II trial for the same indication and granted a special exemption, building on the Orphan Drug Designation the agency awarded the program in 2024.

JOE Media Launches 'Listen to Jordic' Heart-Health Campaign on World Heart Day

Image
JOE Media Launches 'Listen to Jordic' Heart-Health Campaign on World Heart Day

London – September 29, 2026 -- JOE Media Group has launched a heart-health awareness campaign built around a Viking folk character named Jordic, using erectile dysfunction (ED) as an entry point to warn men about underlying cardiovascular disease risk.

Campaign ties ED symptoms to a two-to-five-year cardiovascular warning window

The 'Listen to Jordic' campaign, created by Havas Lynx UK for JOE Media Group, launched on World Heart Day exclusively on JOE.co.uk. Medical literature cited in the campaign indicates ED can precede cardiovascular symptoms by two to five years, offering a critical window for men to seek diagnosis.

Congress Passes ACT for ALS Reauthorization, Extends Programs to 2031

Image
Congress Passes ACT for ALS Reauthorization, Extends Programs to 2031

Los Angeles – – September 29, 2026 -- Congress has passed the Accelerating Access to Critical Therapies (ACT) for ALS Reauthorization Act of 2026 (H.R. 8205), sending the bipartisan bill to the President's desk just two days before the underlying program was set to expire on September 30, 2026.

Senate approval follows House passage, clearing the path for a presidential signature

The legislation cleared the U.S. House of Representatives before the Senate gave final approval, moving the bill to the President for signature. Once enacted, the law will extend core ACT for ALS programs through 2031, continuing federal support for ALS research infrastructure and expanded access to investigational therapies.

IASO Bio's In Vivo CAR-T IASO206 Hits 90% Response Rate in Myeloma Trial

Shanghai – September 29, 2026 -- IASO Biotechnology reported a 90% objective response rate and 90% minimal residual disease (MRD) negativity rate for its BCMA-targeted in vivo CAR-T therapy IASO206, generated via a single intravenous infusion without lymphodepleting chemotherapy, in first-in-human Phase 1 data presented as a late-breaking oral session (LBA-11) at the 2026 International Myeloma Society Annual Meeting.

AMP, Fuse Oncology Launch FuseRx Radiation Workflow Pilot in Syracuse

Image
AMP, Fuse Oncology Launch FuseRx Radiation Workflow Pilot in Syracuse

Syracuse – – September 29, 2026 -- Fuse Oncology and Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company, have launched a proof of concept for FuseRx, a clinical workflow platform for radiation oncology, at AMP's Center of Advanced Radiation Excellence in Syracuse.

Prostate cancer volume drives the test case

The American Cancer Society projects about 333,800 new U.S. prostate cancer cases in 2026, making it the most common cancer in American men after skin cancer. Roughly a third of men with localized disease receive radiation as primary treatment, a pathway that typically starts with a urologist diagnosis before crossing into separate oncology systems.

FDA Weighs Easing Tobacco Product Review Amid 7,500 Illegal Items

Image
FDA Weighs Easing Tobacco Product Review Amid 7,500 Illegal Items

Washington – September 29, 2026 -- The U.S. Food and Drug Administration announced plans to evaluate changes to its application framework for new tobacco products, including e-cigarettes and nicotine pouches, aiming to simplify the pathway for these products to reach the market.

Truth Initiative warns weakened review could undermine public health protections

Kathy Crosby, CEO and President of Truth Initiative, said any changes that reduce the scientific evidence required or diminish the review process would compromise the FDA's regulatory role. The law currently requires the agency to assess a product's components, ingredients, toxicological profile and health impact, alongside risks and benefits to the broader population, including youth and non-users.

Ascletis' Oral ASC50 Cuts Psoriasis Severity 48.9% in Phase I Trial

Image
Ascletis' Oral ASC50 Cuts Psoriasis Severity 48.9% in Phase I Trial

Hong Kong – – September 29, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) reported a 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) scores from a 28-day U.S. proof-of-concept trial of ASC50, an oral small molecule IL-17A inhibitor positioned as a needle-free alternative to injectable antibody therapies for plaque psoriasis.

Once-daily 200 mg dosing matched published efficacy benchmarks for injectable IL-17A antibody secukinumab

The randomized, double-blind, placebo-controlled Phase I study (NCT07024602) enrolled mild-to-moderate plaque psoriasis patients who received once-daily 200 mg oral ASC50 for 28 days. Ascletis said the PASI reduction was comparable to published secukinumab data, though the comparison was not conducted head-to-head.

UMG Becomes First German University Hospital to Deploy MDClone ADAMS

Image
UMG Becomes First German University Hospital to Deploy MDClone ADAMS

Göttingen, Germany – September 29, 2026 -- University Medical Center Göttingen (UMG) has become the first hospital in Germany and the European Union to deploy MDClone's ADAMS platform, layering advanced data utilization tools onto its existing UMG-MeDIC data integration center.

UMG becomes first EU adopter of internationally deployed ADAMS model

ADAMS is already operational at institutions including UChicago Medicine, Manchester University NHS Foundation Trust, and Sheba Medical Center. UMG's rollout marks the model's first entry into a German or EU university hospital, building directly on infrastructure established under Germany's national Medical Informatics Initiative (MII).

Blue Shield Commits $300,000 to Alameda Food Bank's Medicine Program

Image
Blue Shield Commits $300,000 to Alameda Food Bank's Medicine Program

Oakland – – September 29, 2026 -- Blue Shield of California has pledged a $300,000 multi-year investment to Alameda County Community Food Bank (ACCFB), marking the first deployment under the nonprofit insurer's new statewide Food as Health initiative.

Blue Shield becomes the first and largest corporate sponsor of ACCFB's Food as Medicine program

The funding will expand a program that delivers medically supportive food and nutrition education to eligible Medi-Cal members managing chronic conditions. The investment strengthens infrastructure, data collection, and evaluation systems needed to scale the model beyond its current reach.